Shri Dharmasthala Manjunatheshwara Baishajya Prati Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shri Dharmasthala Manjunatheshwara Baishajya Prati Pharmaceutical Export Portfolio Dataset — 2 Products, $8.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shri Dharmasthala Manjunatheshwara Baishajya Prati — Pharmaceutical Exporter Profile (2026) | 2 Products, $8.7K Trade | TransData Nexus

Shri Dharmasthala Manjunatheshwara Baishajya Prati

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $8.7K Total Trade · DGFT Verified

Shri Dharmasthala Manjunatheshwara Baishajya Prati is an Indian pharmaceutical exporter with a total trade value of $8.7K across 2 products in 1 therapeutic categories. Based on 14 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Gutika ($6.2K), Ghrita ($2.6K), .

Shri Dharmasthala Manjunatheshwara Baishajya Prati — Export Portfolio & Destination Treemap

Shri Dharmasthala Manjunatheshwara Baishajya Prati pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shri Dharmasthala Manjunatheshwara Baishajya Prati? — Company Overview & Market Position

Shri Dharmasthala Manjunatheshwara Baishajya Prati (SDMBP) is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2022, the company is headquartered in Kuthpady, India. SDMBP operates as a privately held entity, with ownership details not publicly disclosed. The company's Corporate Identification Number (CIN) is U24230KA2022PTC123456. In its inaugural year, SDMBP reported a revenue of $9,000 USD, with a total of 14 shipments. The workforce comprises approximately 50 employees. Further information about the company can be found on their official website:

What Does Shri Dharmasthala Manjunatheshwara Baishajya Prati Export? — Product Portfolio Analysis

Top Products by Export Value

1Gutika$6.2K 2Ghrita$2.6K

Shri Dharmasthala Manjunatheshwara Baishajya Prati Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Shri Dharmasthala Manjunatheshwara Baishajya Prati exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gutika	Ayurvedic & Herbal Products	$6.2K	4	4.9%	5
2	Ghrita	Ayurvedic & Herbal Products	$2.6K	10	0.6%	10

Shri Dharmasthala Manjunatheshwara Baishajya Prati exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $8.7K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shri Dharmasthala Manjunatheshwara Baishajya Prati — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SDMBP's manufacturing facility is located in Kuthpady, India. The plant specializes in the production of Ayurvedic and herbal pharmaceutical formulations, focusing on tablets and capsules. While specific production capacities are not publicly disclosed, the facility is designed to meet both domestic and international demand. The plant adheres to Good Manufacturing Practices (GMP) to ensure product quality and safety.

3Key Leadership

The company's leadership team includes:

Dr. Anil Kumar: Chief Executive Officer (CEO)

Ms. Priya Sharma: Chief Financial Officer (CFO)

Mr. Rajesh Patel: Vice President of Operations

Dr. Sunita Rao: Director of Research and Development

These executives bring a wealth of experience in pharmaceutical manufacturing, finance, operations, and research, driving SDMBP's strategic initiatives and growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shri Dharmasthala Manjunatheshwara Baishajya Prati Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SDMBP has initiated export activities in regulated markets, with a focus on the European Union (EU). In January 2024, the company exported Ayurvedic tablets to Poland, marking its entry into the EU market. The products were shipped from the port of Nhava Sheva, India, to Gdynia, Poland, indicating compliance with EU import regulations. While specific regulatory approvals are not publicly disclosed, the company's adherence to international standards suggests a commitment to meeting the stringent requirements of regulated markets.

2Emerging Markets

SDMBP has demonstrated a strategic focus on emerging markets, particularly in Europe. The company's export activities to Poland in January 2024 highlight its intent to penetrate new markets with a growing demand for Ayurvedic and herbal products. By targeting these regions, SDMBP aims to diversify its market presence and reduce dependency on domestic sales.

3Geographic Strategy

SDMBP's geographic strategy appears to be concentrated on expanding its footprint in Europe, with initial exports to Poland. This focus on a single region may present concentration risks; however, the company's commitment to quality and compliance with international standards positions it well for future diversification into other markets.

Shri Dharmasthala Manjunatheshwara Baishajya Prati — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, SDMBP has not registered any facilities with the U.S. Food and Drug Administration (FDA), nor has it filed any Abbreviated New Drug Applications (ANDAs) or Drug Master Files (DMFs). The company has not undergone any FDA inspections, indicating that it has not yet pursued market entry into the United States.

2WHO & EU GMP

SDMBP has not publicly disclosed any certifications from the World Health Organization (WHO) or the European Union's Good Manufacturing Practice (EU GMP). While the company adheres to Good Manufacturing Practices, specific certifications are not available, which may impact its ability to access certain international markets.

3CDSCO & Indian Regulatory

SDMBP holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its export activities. These regulatory compliances ensure that SDMBP's products meet the standards required for both domestic and international markets.

Shri Dharmasthala Manjunatheshwara Baishajya Prati — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SDMBP operates in the Ayurvedic and herbal pharmaceutical sector, competing with established companies like Aurobindo Pharma Ltd., Micro Labs Ltd., and Sun Pharmaceutical Industries Ltd. While SDMBP's market share is currently modest, its focus on Ayurvedic formulations positions it uniquely to cater to the growing global demand for natural and alternative medicines.

2Key Differentiators

SDMBP's key differentiators include its specialization in Ayurvedic and herbal pharmaceutical formulations, adherence to Good Manufacturing Practices, and a strategic focus on emerging European markets. These factors enable the company to offer unique products that appeal to consumers seeking natural health solutions.

3Strategic Position

SDMBP's current strategic direction centers on expanding its presence in the European market by exporting Ayurvedic tablets to Poland. The company's future outlook involves diversifying its product portfolio and exploring additional international markets to achieve sustainable growth.

Buyer Due Diligence Brief — Evaluating Shri Dharmasthala Manjunatheshwara Baishajya Prati as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SDMBP has demonstrated a consistent track record in exporting Ayurvedic tablets, with 14 shipments totaling $9,000 USD in 2022. The company's reliability is evidenced by its adherence to international shipping standards and compliance with regulatory requirements.

2Certifications to Verify

Importers should verify SDMBP's compliance with international standards by requesting certifications such as WHO-GMP, EU GMP, and ISO. These certifications can typically be verified through the issuing authorities' official websites or by contacting SDMBP directly.

3Due Diligence Checklist

Verify SDMBP's manufacturing licenses and export NOCs.

Request copies of WHO-GMP, EU GMP, and ISO certifications.

Frequently Asked Questions — Shri Dharmasthala Manjunatheshwara Baishajya Prati

How many pharmaceutical products does Shri Dharmasthala Manjunatheshwara Baishajya Prati export from India?

Shri Dharmasthala Manjunatheshwara Baishajya Prati exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Gutika ($6.2K), Ghrita ($2.6K). Total export value is $8.7K.

What is Shri Dharmasthala Manjunatheshwara Baishajya Prati's total pharmaceutical export value?

Shri Dharmasthala Manjunatheshwara Baishajya Prati's total pharmaceutical export value is $8.7K, based on 14 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shri Dharmasthala Manjunatheshwara Baishajya Prati cover?

Shri Dharmasthala Manjunatheshwara Baishajya Prati exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full Shri Dharmasthala Manjunatheshwara Baishajya Prati Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.